JSA advised Temasek in its investment in Molbio Diagnostics.
Goa-based Molbio Diagnostics is known for its ‘Truenat’ technology — a portable, battery-operated real-time PCR platform that can be used for testing infectious diseases, including TB, COVID-19, Hepatitis-C virus, human papillomavirus, influenza and vector-borne diseases like dengue, chikungunya and malaria. The Company’s Truenat portable technology platform enables early and accurate diagnosis of infectious diseases and initiation of correct treatment right at the first point of contact and can be deployed at all levels of the healthcare chain, including very remote and inaccessible areas.
Motilal Oswal Alternates is an existing investor in Molbio Diagnostics. JSA had advised Motilal Oswal at the time of its investment as well.
JSA Transaction Team comprised Partners – Vikram Raghani, & Birbahadur Sachar, Principal Associate – Yashvi Singh, and Associate – Rishabh Sheth.
JSA Competition Team comprised Partner & Head of Practice (Competition Law) – Vaibhav Choukse, Principal Associate – Ela Bali, Senior Associate – Aditi Khanna, and Associate – Faiz Siddiqui.
Bir is a member of JSA’s Corporate and Finance practice. He specialises in mergers & acquisitions (both listed and unlisted) and private equity (both listed and unlisted).
Ela is a partner with JSA’s competition law practice with 10 years of experience. She represents and advises clients across different sectors on enforcement and merger control matters before the Competition Commission of India (CCI), National Company Law Appellate Tribunal (NCLAT), Delhi and Bombay High Court, and the Supreme Court of India (SC).
Vaibhav is a Partner with Firm’s Competition Law Practice with over 15 years’ experience.
Vikram is a Partner with the Corporate Practice at JSA. His areas of practice include mergers & acquisitions, private equity and securities laws (including capital markets). He has been involved in private equity and mergers & acquisitions transactions also focusing on public market investments and M&A.